Jefferies has lowered its rating on Datadog to Hold from Buy, citing the stock's significant 94% year-to-date gain which has stretched its valuation. The firm remains positive on the company's fundamentals as an AI beneficiary but awaits a more attractive entry point.
Options data suggests traders are anticipating a 5.8% move in Ford's stock price following its July 28 earnings release. Historical performance shows the automaker's shares have exceeded these volatility expectations in five of the last eight quarters.
Norway's benchmark stock index closed at a one-month high on Tuesday, buoyed by gains in healthcare and utilities. The advance coincided with a rally in global oil prices, which boosted major energy stocks on the exchange.
Options traders are pricing in a potential 10% move for Corning shares following its earnings release on July 28. The stock has a history of volatile post-earnings reactions, often exceeding market expectations.
Options market data indicates a potential 9.7% swing for Avis Budget Group shares following its upcoming earnings report on July 28. The stock has a history of volatile reactions, exceeding the implied move in five of its last eight releases.
Israel's benchmark TA 35 index closed higher on Tuesday, buoyed by strong performance in the insurance, oil & gas, and financial sectors. Technology shares like Tower Semiconductor were among the top performers of the session.
Options traders are pricing in a potential 9.1% swing for Skyworks Solutions (NASDAQ:SWKS) stock following its earnings report scheduled for July 28. This expectation for volatility is slightly higher than in the previous quarter.
Executives at firms including Tech Innovations Inc. and Acme Corp have sold significant blocks of their company's shares, according to recent SEC filings. The sales, some executed under pre-arranged plans, come amid varied stock performances across the companies.
Shares of the Danish drugmaker fell as it sued competitor Eli Lilly over advertising, a move investors interpreted as a sign of mounting pressure in the lucrative weight-loss drug market.
